HEPION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
HEPION PHARMACEUTICALS, INC. (HEPA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $13.87 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2025-11-12
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $13.87K.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $2.70M, a 35.71% decline from fiscal 2022.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $4.20M, a 4.55% decline from fiscal 2021.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $4.40M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $13.87K derived: sum of 2 quarters · filed 2025-11-12 | $13.87K 10-Q · filed 2025-11-12 | $13.87K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2025-06-30 | $13.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $13.87K 10-Q · filed 2025-08-14 | $13.87K derived: sum of 3 quarters · filed 2025-08-14 | $13.87K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-19 | $0.00 derived: sum of 2 quarters · filed 2025-05-19 | $0.00 derived: sum of 3 quarters · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2025-05-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 derived: sum of 3 quarters · filed 2025-11-12 | $700.00K 10-Q · filed 2025-05-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $700.00K 10-Q · filed 2025-11-12 | $800.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $700.00K 10-Q · filed 2025-08-14 | $800.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.20M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $700.00K 10-Q · filed 2024-05-21 | $800.00K derived: sum of 2 quarters · filed 2025-04-08 | $1.20M derived: sum of 3 quarters · filed 2025-04-08 | $2.90M derived: sum of 4 quarters · filed 2025-04-08 | |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08 | $500.00K derived: sum of 2 quarters · filed 2025-04-08 | $2.20M derived: sum of 3 quarters · filed 2025-04-08 | $2.70M 10-K · filed 2025-04-08 | |
| 2023-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.10M derived: sum of 2 quarters · filed 2024-11-14 | $2.60M 10-Q · filed 2024-11-14 | $2.50M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.20M 10-Q · filed 2024-08-13 | $2.10M derived: sum of 3 quarters · filed 2024-08-13 | $2.40M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-21 | $400.00K derived: sum of 2 quarters · filed 2024-05-21 | $700.00K derived: sum of 3 quarters · filed 2024-05-21 | $4.50M derived: sum of 4 quarters · filed 2024-05-21 | |
| 2022-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $200.00K derived: sum of 2 quarters · filed 2024-04-16 | $4.00M derived: sum of 3 quarters · filed 2024-04-16 | $4.20M 10-K · filed 2024-04-16 | |
| 2022-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | $4.10M derived: sum of 2 quarters · filed 2023-11-20 | $4.30M 10-Q · filed 2023-11-20 | $4.60M derived: sum of 4 quarters · filed 2023-11-20 | |
| 2022-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.00M 10-Q · filed 2023-08-14 | $4.30M derived: sum of 3 quarters · filed 2023-08-14 | $5.80M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-12 | $500.00K derived: sum of 2 quarters · filed 2023-05-12 | $2.00M derived: sum of 3 quarters · filed 2023-05-12 | $4.60M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | $1.80M derived: sum of 2 quarters · filed 2023-04-10 | $4.40M derived: sum of 3 quarters · filed 2023-04-10 | $4.40M 10-K · filed 2023-04-10 | |
| 2021-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.10M derived: sum of 2 quarters · filed 2022-11-14 | $4.10M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $2.60M 10-Q · filed 2022-08-15 | $2.56M 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | ||||
| 2018-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $600.00K 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $1.00M 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | $600.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |